Clinical Trial Update: A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate escalating doses of everolimus (RAD001) in combination with the IGF-1 receptor antibody R1507 in patients with advanced solid tumors; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Everolimus (RAD001) (everolimus)
• R1507

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 1 | Status: TERMINATED